Board of directors

Olivier joined the Andera Partners’ Life Sciences team based in Paris in 2006. Before that he worked with 3i in Venture Healthcare, first investing out of Munich, later out of Paris.

Prior to that, Olivier was a consultant with Mercer Management Consulting in Munich and Paris. Olivier holds a PhD in Biology from the Munich Institute für Genetik und Mikrobiology and has performed his scientific research in Munich and Oxford University.

Olivier is a Director of Allecra Therapeutics, JenaValve Technologies, MMI, Autonomic Technologies and MedLumics, and was a director of Novexel, Endosense, Sapiens and Probiodrug , SuperSonic Imagine and Noxxon Pharma up until their respective acquisitions or listings.

Claudio Rumazza is a venture capital investor, Partner at Innogest Capital, where he focuses on healthcare investments and in particular on medical devices, diagnostics and digital health.

Claudio currently serves on the Board or as investor observer of Erydel SpA, Newronika Srl, Anaconda Biomed SA, Angiodroid Srl, Pi-Cardia Ltd and CVLab SpA. Prior to Innogest, Claudio held various positions as a corporate finance executive at Finn-Power Group and Prima Industrie Group and he stated his career as a management consultant.

Claudio has a bachelor’s degree economics from the University of Torino.

More than 12 years of experience in business development, technology transfer and in early stage investment. He is Director of the Life Science Invest Fund at Caixa Capital Risc and he serves on the Board of Directors at MedLumics, Aelix Therapeutics, Minoryx, iProteos, Proteodesign and Laboratoris Sanifit.

Pablo, gratuated in Chemistry from the University of Buenos Aires, holds a Ph.D. in Organic Chemistry from the University of Barcelona and a postdoc. Fulbright Fellow at the Department of System Biology at Hardvard University. Pablo has wide experience in technology transfer as Senior Innovation and Technology Transfer Manager at Botin Foundation  and as a Director of the Technology and Business Development Office at the Center for Genome Regulation.

Giovanni Leo is a venture partner at Innogest Capital since 2017. Prior to Innogest he held the position of VP of RND at St Jude Medical since the acquisition of Endosense in 2013, which he co-founded to develop a novel technology for the catheter ablation treatment of cardiac arrhythmias.

Formerly he was the director of the Geneva offices for Acrostak Corp., a Boston-Scientific funded medical device company that developed the only European system for vascular brachytherapy. He was also co-founder of Isotopes and Metals Ltd., an emerging medical device company focused on technology for prostate and gynecological brachytherapy. Giovanni previously held a software quality manager position at LeCroy Corp.

Jim serves as Chief Executive Officer and a member of the Board of Directors for MedLumics bringing 30 years of extensive operational experience in medical device design, development, and commercialization.

Prior to joining MedLumics, Jim served as Partner in Seroba Life Sciences Limited, a Dublin based venture capital firm. Jim is a serial entrepreneur founding multiple medical device start-ups in the cardiovascular field serving as CEO of Verso Technologies, Inc., Apica Cardiovascular Ltd., Advanced Medical Technologies, Inc. (APK), and MitralSolutions, Inc. Earlier in his career, Jim held Director level positions at global medical device companies such as Medtronic, AVE, and Guidant.